Spots Global Cancer Trial Database for lenvatinib mesylate

Every month we try and update this database with for lenvatinib mesylate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)	NCT02973997	Columnar Cell V... Follicular Vari... Metastatic Thyr... Metastatic Thyr... Poorly Differen... Recurrent Diffe... Recurrent Thyro... Recurrent Thyro... Stage III Diffe... Stage III Thyro... Stage III Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Diffe... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Diffe... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Diffe... Stage IVC Thyro... Stage IVC Thyro... Tall Cell Varia... Thyroid Gland H... Unresectable Di... Unresectable Th...	Laboratory Biom... Lenvatinib Lenvatinib Mesy... Pembrolizumab	18 Years -	Academic and Community Cancer Research United
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer	NCT04887805	Advanced Pancre... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	Lenvatinib Mesy... Pembrolizumab	18 Years -	City of Hope Medical Center
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer	NCT02788708	Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom...	Lenvatinib Mesy... Paclitaxel Pharmacological...	18 Years -	Ohio State University Comprehensive Cancer Center
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer	NCT02788708	Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom...	Lenvatinib Mesy... Paclitaxel Pharmacological...	18 Years -	Ohio State University Comprehensive Cancer Center
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)	NCT02430714	Thyroid Neoplas...	Lenvatinib	-	Eisai Inc.
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer	NCT04887805	Advanced Pancre... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	Lenvatinib Mesy... Pembrolizumab	18 Years -	City of Hope Medical Center
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer	NCT04929392	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Aden... Esophageal Squa... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Carboplatin Endoscopic Biop... External Beam R... Lenvatinib Mesy... Paclitaxel Pembrolizumab Resection	18 Years -	City of Hope Medical Center
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer	NCT04929392	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Aden... Esophageal Squa... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Carboplatin Endoscopic Biop... External Beam R... Lenvatinib Mesy... Paclitaxel Pembrolizumab Resection	18 Years -	City of Hope Medical Center
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer	NCT02788708	Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom...	Lenvatinib Mesy... Paclitaxel Pharmacological...	18 Years -	Ohio State University Comprehensive Cancer Center
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)	NCT02430714	Thyroid Neoplas...	Lenvatinib	-	Eisai Inc.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: